Find in Library

New antitubercular agents with either a novel mode of action or novel mode of inhibition are urgently needed to overcome the threat of drug-resistant tuberculosis (TB). The present study profiles new arylated quinoline carboxylic acids (QCAs) having activity against replicating and non-replicating <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>), the causative agent of TB. Thus, the synthesis, characterization, and in vitro screening (MABA and LORA) of 48 QCAs modified with alkyl, aryl, alkoxy, halogens, and nitro groups in the quinoline ring led to the discovery of two QCA derivatives, <b>7i</b> and <b>7m,</b> adorned with C-2 2-(naphthalen-2-yl)/C-6 1-butyl and C-2 22-(phenanthren-3-yl)/C-6 isopropyl, respectively, as the best <i>Mtb</i> inhibitors. DNA gyrase inhibition was shown to be exhibited by both, with QCA <b>7m</b> illustrating better activity up to a 1 μM test concentration. Finally, a docking model for both compounds with <i>Mtb</i> DNA gyrase was developed, and it showed a good correlation with in vitro results.